Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 805
  • Home
  • Print this page
  • Email this page
BRIEF COMMUNICATION
Year : 2009  |  Volume : 57  |  Issue : 2  |  Page : 146-148

Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents


Retina Foundation, Ahmedabad, India

Correspondence Address:
Manish Nagpal
Retina Foundation, Shahibaug, Ahmedabad- 380 004, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.45507

Rights and Permissions

Intravitreal anti-vascular endothelial growth factor (VEGF) agents have obtained acceptance as the mainstay in the management strategy of subfoveal choroidal neovascular membranes (CNVM) due to varying etiologies. Few drawbacks include need for repeated intravitreal injections, with its adjunct risks, and the lack of a predefined treatment end point, which can cause doubts and uncertainty in the mind of the patient. Furthermore, it remains a significant financial burden for the patient. Herein we report our data of three patients who were reluctant for further re-injections of anti-VEGF agents and were therefore offered surgical removal of the CNVM by submacular surgery as an alternative treatment plan.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1776    
    Printed50    
    Emailed0    
    PDF Downloaded218    
    Comments [Add]    

Recommend this journal